Bio-Rad Laboratories Inc. Hits New 52-Week High at $127.89 (BIO)
Bio-Rad Laboratories (NYSE:BIO)’s share price reached a new 52-week high during trading hours on Thursday, American Banking News.com reports. The company traded as high as $127.89 and last traded at $127.85, with a volume of 93,764 shares traded. The stock had previously closed at $124.35.
Several analysts have recently commented on the stock. Analysts at Zacks downgraded shares of Bio-Rad Laboratories from a “neutral” rating to an “underperform” rating in a research note to investors on Tuesday, December 17th. They now have a $120.40 price target on the stock. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $129.80.
Bio-Rad Laboratories has a 1-year low of $109.76 and a 1-year high of $128.58. The stock’s 50-day moving average is $122. and its 200-day moving average is $119.7. The company has a market cap of $3.683 billion and a P/E ratio of 40.15.
Bio-Rad Laboratories (NYSE:BIO) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.25) EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.91 by $1.16. The company had revenue of $505.10 million for the quarter, compared to the consensus estimate of $529.02 million. During the same quarter in the prior year, the company posted $1.48 earnings per share. The company’s quarterly revenue was up 1.3% on a year-over-year basis. Analysts expect that Bio-Rad Laboratories will post $3.95 EPS for the current fiscal year.
Bio-Rad Laboratories, Inc (NYSE:BIO) manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.